石药、中生制药和石四药领药品股普涨4+7药品采购座谈会纪要透露利好
格隆汇7月15日丨港股市场药品股普涨,其中,石药集团涨超8%,福森药业涨超5%,中国生物制药、复星医药和石四药涨超4%。一份流传出的4+7药品集中采购座谈会纪要透露,第二轮招标品种仍是先前的25个,但招标的范围要从4+7城市拓展到全国所有省份及地区,包括全部地区的公立医院、定点民营医院、军队医院。约定用量方面,纪要透露,若一家中标给予企业50%的量,两家中标给予60%的量,三家中标给70%的量,但在价格上要求更低。据一位接近此次座谈会的业内人士透露,此次带量采购仍然由上海药事所组织实施,下周方案报国务院批准,估计8月初公布方案,10月就有望开展。业内分析人士认为:纪要透露出的内容整体偏向利好,取消哦一家中标,允许多家中标;降价幅度可能没有去年大;集采全国推广速度加快,份额变多。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.